Jacobs Levy Equity Management
STRO icon

Jacobs Levy Equity Management’s Sutro Biopharma STRO Stock Holding History

Jacobs Levy Equity Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44,575
Closed -$387K – 1055
2025
Q3 		$387K Buy
+44,575
New +$379K ﹤0.01% 854
2025
Q1 		– Sell
-85,937
Closed -$1.58M – 1196
2024
Q4 		$1.58M Buy
85,937
+3,762
+5% +$115K 0.01% 648
2024
Q3 		$2.84M Sell
82,175
-22,844
-22% -$895K 0.01% 535
2024
Q2 		$3.08M Sell
105,019
-1,933
-2% -$76.4K 0.01% 530
2024
Q1 		$6.04M Buy
106,952
+72,924
+214% +$3.22M 0.03% 389
2023
Q4 		$1.46M Sell
34,028
-8,541
-20% -$271K 0.01% 657
2023
Q3 		$1.48M Sell
42,569
-14,570
-25% -$635K 0.01% 611
2023
Q2 		$2.66M Sell
57,139
-9,321
-14% -$464K 0.02% 524
2023
Q1 		$3.07M Sell
66,460
-288
-0.4% -$18.3K 0.02% 488
2022
Q4 		$5.39M Sell
66,748
-7,575
-10% -$526K 0.04% 379
2022
Q3 		$4.13M Sell
74,323
-27,380
-27% -$1.62M 0.03% 429
2022
Q2 		$5.3M Buy
101,703
+39,655
+64% +$2.22M 0.04% 409
2022
Q1 		$5.1M Buy
+62,048
New +$5.9M 0.03% 415
2021
Q2 		– Sell
-10,658
Closed -$2.43M – 1113
2021
Q1 		$2.43M Sell
10,658
-5,072
-32% -$1.2M 0.02% 557
2020
Q4 		$3.42M Buy
15,730
+10,429
+197% +$1.73M 0.03% 468
2020
Q3 		$533K Sell
5,301
-972
-15% -$91.8K 0.01% 780
2020
Q2 		$487K Sell
6,273
-280
-4% -$26.9K 0.01% 793
2020
Q1 		$668K Buy
6,553
+20
+0.3% +$2.1K 0.01% 707
2019
Q4 		$719K Buy
6,533
+3,454
+112% +$356K 0.01% 736
2019
Q3 		$280K Sell
3,079
-1,258
-29% -$127K ﹤0.01% 792
2019
Q2 		$494K Sell
4,337
-16
-0.4% -$1.76K 0.01% 741
2019
Q1 		$496K Buy
+4,353
New +$453K 0.01% 775

Other funds holding STRO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Jacobs Levy Equity Management's STRO Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Sutro Biopharma (STRO) in Q4 2025, closing a stake of 44,575 shares — an estimated $387K sold.

Jacobs Levy Equity Management first reported a position in STRO in Q1 2019 and held it in 22 quarters. The position peaked at $6.04M in Q1 2024. 63 funds tracked by Wall St. Rank hold STRO as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Sutro Biopharma position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 44,575 Sutro Biopharma shares in Q4 2025, an estimated $387K.
  • Jacobs Levy Equity Management first reported a position in Sutro Biopharma in Q1 2019 and held it in 22 quarters.
  • Jacobs Levy Equity Management's Sutro Biopharma position peaked at $6.04M in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.